Lifestyle

The Prescription Drug Markup Nobody Explains to You

By Curtis Jones · August 30, 2026

You pay $85 for a medication that costs $3 to manufacture. The other $82 doesn’t go to one company. It goes to six — and none of them have any incentive to lower the price.

The prescription drug supply chain in the United States involves more intermediaries than any other healthcare product. Each one takes a margin. None of them is transparent about it. And the system is designed so that no single entity appears responsible for the final price you pay.

The manufacturer sets a list price based on what the market will bear — not what the drug costs to make. The wholesale acquisition cost — the price the manufacturer charges distributors — is the anchor for the entire pricing chain. For a generic drug, this number often bears little relationship to production cost. For a brand-name drug, the list price may exceed production cost by 1,000% or more. The manufacturer’s argument is that the price reflects research and development costs, which is true for some drugs and irrelevant for others — particularly generics that have been off-patent for decades.

The wholesaler adds 2% to 5%. Three companies — McKesson, AmerisourceBergen, and Cardinal Health — distribute roughly 90% of all pharmaceuticals in the U.S. They buy from manufacturers, store the drugs, and sell to pharmacies. Their margin is relatively thin per transaction but enormous in aggregate, given that the industry handles more than $500 billion in drug sales annually.

The PBM takes a cut from both sides. Pharmacy benefits managers negotiate rebates from manufacturers in exchange for favorable formulary placement. Those rebates are calculated as a percentage of the list price — which means the PBM profits more when list prices go up. The PBM also sets the reimbursement rate paid to your pharmacy, often below the pharmacy’s acquisition cost. The difference between what the PBM collects from your insurer and what it pays your pharmacy is called “spread pricing” — and it goes straight to the PBM.

The pharmacy’s margin is being squeezed to zero. Independent pharmacies report that PBM reimbursement rates frequently fall below their cost to acquire the drug. DIR fees — clawed back after the transaction — can turn a profitable prescription into a net loss. This margin compression is driving independent pharmacy closures across the country, reducing access for the patients who relied on them.

Your insurer determines your copay based on the inflated price, not the negotiated one. Your copay or coinsurance is typically calculated as a percentage of the drug’s list price — not the net price after rebates. The rebate the PBM negotiated doesn’t reduce what you pay at the counter. It reduces what the insurer pays. You’re charged a percentage of a number that everyone in the chain knows isn’t the real price.

The patient is the only participant who pays full price. The manufacturer collects the list price minus the rebate. The PBM collects the rebate and the spread. The insurer collects your premium. The pharmacy collects whatever the PBM allows. Every entity in the chain has a negotiated arrangement that limits what they actually pay. The patient — the only person in the system without negotiating power — absorbs whatever number appears on the screen.

The system isn’t broken. It’s working exactly as designed — for everyone except the person picking up the prescription.